Pfizer (NYSE:PFE – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.750-2.950 for the period, compared to the consensus earnings per share estimate of 2.650. The company issued revenue guidance of $61.0 billion-$64.0 billion, compared to the consensus revenue estimate of $61.2 billion. Pfizer also updated its FY24 guidance to $2.75-$2.95 EPS.
Pfizer Stock Performance
PFE traded down $0.22 on Thursday, hitting $28.30. 37,223,971 shares of the stock traded hands, compared to its average volume of 37,136,637. The business has a fifty day moving average price of $29.06 and a two-hundred day moving average price of $28.56. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $160.37 billion, a PE ratio of 38.38, a P/E/G ratio of 0.99 and a beta of 0.67. Pfizer has a 52 week low of $25.20 and a 52 week high of $31.54.
Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.17) earnings per share. On average, research analysts predict that Pfizer will post 2.67 EPS for the current fiscal year.
Pfizer Dividend Announcement
Wall Street Analyst Weigh In
PFE has been the topic of several research analyst reports. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $33.58.
Get Our Latest Research Report on PFE
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Five stocks we like better than Pfizer
- About the Markup Calculator
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- The Significance of Brokerage Rankings in Stock Selection
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.